

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**VUORINEN et al**

Serial No. **08/925,321**

Filed: **September 8, 1997**

For: **METHOD OF TREATING CELLULOSIC PULP**



Atty. Ref.: **30-336**

Group: **1731**

Examiner: **Alvo**

**August 23, 1999**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RECONSIDERATION OF NOTIFICATION OF NON-COMPLIANCE**  
**WITH THE REQUIREMENTS OF 37 CFR §1.192(c) AND**  
**CONTINGENT PETITION FOR THE REVIEW OF THE**  
**PROPRIETY THEREOF**

Reconsideration is respectfully requested of the Notification of Non-Compliance with the requirements of 37 CFR §1.192(c). If this Notification of Non-Compliance is not withdrawn and the appeal brief accepted, then this is a petition for review of the propriety of the Notification. While it is believed that no fee is associated therewith, any fees may be charged to our Account No. 14-1140, Order No. 30-336.

37 CFR 1.192(c)(7) provides "Merely pointing out differences in what the claims cover is not an argument as to why the claims are separately patentable." In this case, under no stretch of the imagination have appellants violated that provision. Appellants have not only pointed out that the features in the claims are not shown in the references but have specifically provided (see the last sentence in the second and third paragraphs on page 20 of the Brief) that with respect to all of the claims involved in each situation "nor is there any reason why one of ordinary skill in the art would employ what is specifically called for therein (or any *prima facie* case established in the Final Rejection)". That is, it is also argued that not only is what is set forth in all of the claims

#23/301  
18-26-99

RECEIVED  
AUG 25 1999  
TC 1100 MAIL ROOM

not shown in the prior art, but that there is no reason why one of ordinary skill in the art would employ what is set forth therein, and therefore no *prima facie* case of obviousness. The Federal Circuit and CCPA before it have clearly and unequivocally required the Patent & Trademark Office in the first instance to establish a *prima facie* case of obviousness. See *In re Warner*, 154 USPQ 173, 177-78 (CCPA 1967).

In determining the propriety of a rejection under 35 USC §103, it is well settled that the obviousness of an invention cannot be established by combining the teachings of the prior art absent some teaching, suggestion or incentive supporting the combination. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596, 1598, 1599 (Fed. Cir. 1988); *Ashland Oil, Inc. v Delta Resins and Refractories, Inc.*, 776 F.2d 281, 227 USPQ 657 (Fed. Cir. 1985); *ACS Hospital Systems, Inc. v Montefiore Hospital*, 732 F.2d 1572, 221 USPQ 929 (Fed.Cir. 1984). The law of the Federal Circuit is that "[a] *prima facie* case of obviousness is established when the teachings from the prior art itself would appear to have suggested the claimed subject matter to a person of ordinary skill in the art." *In re Rinehart*, 531 F.2d 1048, 1051, 189 USPQ 143, 147 (CCPA 1976), emphasis added. See also *In re Lulu*, 747 F.2d 703, 705, 223 USPQ 1257, 1258 (Fed. Cir. 1984) ("In determining whether a case of *prima facie* obviousness exists, it is necessary to ascertain whether the prior art teachings would appear to be sufficient to one of ordinary skill in the art to suggest making the claimed substitution or other modification." (emphasis added)).

Appellants arguments pointing out that the Patent & Trademark Office has completely failed in establishing a *prima facie* case of obviousness with respect to the claims is entirely appropriate argument, and it is for the Board of Appeals to determine

whether or not that will result in reversal of the Final Rejection, not the province of the Examiner writing the Final Rejection to deny appellants the right to have that consideration.

The consideration of appellants' arguments should also be specifically evaluated in the context of the Final Rejection. While criticizing appellants for not specifically arguing each individual claim, the Final Rejection does not even mention the claims at issue here. Reading the Notification of Non-Compliance one would expect that the Final Rejection contained detailed rejections of claims 13, 15, 21, 3, 18, 20, and 22 through 28. However, upon inspection of the Final Rejection one sees that only claims 3, 20, and 21 are even mentioned. The other claims are completely and unequivocally ignored. Apparently what the Notification of Non-Compliance wants is for appellants to argue against themselves, or to assume what the reasoning is for the rejections of the individual claims in the shotgun rejection provided in the Final Action, and then argue against that assumption. There is no basis in the Rules of Practice, the statute, or the MPEP for that approach, and it is completely inappropriate to expect appellants to do any more than they have (which completely fulfills the requirements of 37 CFR 1.192) under these circumstances.

With respect to the allegation that claims 3, 18, 20 and 27 have been argued as a "single group" and there is no argument "as to why the claims are separately patentable", these claims are entirely distinct claims, with different limitations, and claims 18, 20, and 27 were argued earlier (than on page 18 -- namely see, for example, page 17, including footnote 2), and therefore they are patentably distinct from each other. Again, 37 CFR 1.192 does not require appellants to argue against themselves,

**VUORINEN et al**  
Serial No. **08/925,321**


to assume positions in the Final Rejection that are not there, or to supply for the Patent & Trademark Office the items missing from the Final Rejection in establishing a *prima facie* case of obviousness.

Early withdrawal of the Notification of Non-Compliance and early reversal of the Final Rejection are respectfully requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:

A handwritten signature in dark ink, appearing to read 'Robert A. Vanderhye', is written over a horizontal line.

**Robert A. Vanderhye**

Reg. No. **27,076**

**RAV:Imy**

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100